The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.
All News
Article
Article
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
Article
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
Pedro Castillo
Tweet
Excellent talk by Dr. Anna Molto. Characteristics of spondyloarthritis, noting some patients with PsA have radiographic and non-radiographic axial SpA.
#ACR21 6S403 @RheumNow https://t.co/ycftOMrWO9
Dr. Antoni Chan
Tweet
Are we getting closer to personalised medicine in #psoriaticarthritis Predicting progressors vs non-progressors using proteomics identified 103 candidate biomarker peptides that will discriminate the two groups @RheumNow #ACR21 #ACRBest Abst#0449 https://t.co/obDXTz3i5N
Excellent scientific session on #SpA at #ACR21 right now- especially like this clear diagram of pathophysiology and useful summary slide from Dr Nigil Haroon on differences between #axSpA and axial #PsA
@RheumNow https://t.co/F7Ns7e9HQI
Dr. Antoni Chan
Tweet
“The differences and similarities between axial disease in psoriatic arthritis vs axial spondyloarthritis is just at the cusp of discovery” Nigil Haroon at session 6S403 @RheumNow #ACR21
Richard Conway
Tweet
Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN
Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment
⬆️ACR20 response compared to pbo
⬆️secondary endpoints
⭐️no new safety signals
Abs#453
#ACR21 #ACRBest @RheumNow
https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5
swethaann23
Tweet
#ACR21 #ACRBest @Rheumnow
Abst #0452 Raychaudhuri et al.
TB-PET/CT indices ➡️ disease outcome measures in PsA
Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA
Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS
Can we predict who which PsA pts will be radiographic progressors?
Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors
More data needed
#ACR21
@RheumNow
https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH
Dr. Antoni Chan
Tweet
New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro
Interesting study on immune cell profiling in PsA pts
⭐️variability in T cell sub-populations in PsA pts
⭐️no difference in lymphocyte cell populations before/after therapy
Abs#0056
https://t.co/16PYxaxT2S
#ACR21
@RheumNow https://t.co/dWaJr7hJ1p
Eric Dein
Tweet
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19.
▶️150 mg RZB vs Placebo
⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI
⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn
⭐️No safety signal
https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉phase 3 DBRPCT 24 weeks
👉150 mg week 0,4, 16 weeks
👉improved ACR20,ACR50,ACR70
👉improved PASI90
👉improved HAQ-DI
👉no increased safety signals
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
sheila
Tweet
Promising results of Risankizumab for #psoriaticarthritis
🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo
🔸Well tolerated and showed no safety signals
@RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy
